TheraRadar

Dizal

Pre-Approval PRO BETA
36
Total Trials
3
Phase 3
18
Phase 2
18
Recruiting
301
Score

Pipeline by Phase

Phase 3
3
Phase 2
18
Phase 1
24

Therapeutic Focus

Healthy Volunteers Non-small Cell Lung Cancer Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Lymphoma, Non-Hodgkin Non Small Cell Lung Cancer

Clinical Trials (36)

NCT07139873 Phase 3 RECRUITING

A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)

Started: 9/8/2025

NCT07234162 Phase 3 RECRUITING

A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)

Started: 5/13/2024

NCT05668988 Phase 3 ACTIVE NOT RECRUITING

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Started: 12/13/2022

NCT07294365 Phase 2 RECRUITING

A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

Started: 1/15/2026

NCT06295432 Phase 2 RECRUITING

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Started: 6/1/2023

NCT07154264 Phase 2 RECRUITING

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

Started: 9/22/2025

NCT06539182 Phase 2 RECRUITING

DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)

Started: 4/29/2024

NCT06276283 Phase 2 RECRUITING

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Started: 2/15/2023

NCT06539195 Phase 2 ACTIVE NOT RECRUITING

DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9)

Started: 3/13/2024

NCT06511895 Phase 2 COMPLETED

AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)

Started: 5/31/2022

NCT06511869 Phase 2 COMPLETED

AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26)

Started: 3/17/2022

NCT05712902 Phase 2 ACTIVE NOT RECRUITING

Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)

Started: 7/19/2021

NCT07496229 Phase 1 RECRUITING

Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)

Started: 4/15/2026

NCT07059650 Phase 1 RECRUITING

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)

Started: 8/19/2025

NCT06905197 Phase 1 RECRUITING

A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)

Started: 5/13/2025

NCT07328217 Phase 1 RECRUITING

A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors

Started: 1/29/2026

NCT06813365 Phase 1 RECRUITING

Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)

Started: 6/12/2024

NCT07070440 Phase 1 RECRUITING

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

Started: 7/16/2025

NCT05824585 Phase 1 RECRUITING

DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Started: 5/15/2023

NCT07454863 Phase 1 COMPLETED

A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15)

Started: 3/16/2026

NCT03974022 Phase 1 ACTIVE NOT RECRUITING

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)

Started: 7/9/2019

NCT04105010 Phase 1 COMPLETED

Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)

Started: 9/10/2019

NCT04509596 Phase 1 COMPLETED

DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer

Started: 9/21/2020

NCT04148742 Phase 1 WITHDRAWN

Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)

Started: 8/1/2021

NCT05844956 Phase 1 COMPLETED

A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)

Started: 6/1/2022

NCT06084104 Phase 1 COMPLETED

DZD9008 PK Study in Hepatic Impairment Subjects

Started: 10/17/2023

NCT05926180 Phase 1 COMPLETED

Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)

Started: 7/31/2023

NCT05418582 Phase 1 COMPLETED

Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine

Started: 1/25/2022

NCT05486949 Phase 1 COMPLETED

Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine

Started: 7/27/2022

NCT04634344 Phase 1 TERMINATED

Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC

Started: 4/12/2021

NCT04932005 Phase 1 COMPLETED

A Study of DZD2269 in Healthy Adult Participants

Started: 6/29/2021

NCT04909242 Phase 1 COMPLETED

Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult Participants

Started: 4/21/2021

NCT05159895 Phase 1 COMPLETED

Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects

Started: 9/24/2021

NCT03728023 Phase 1 COMPLETED

A Study of AZD4205 in Healthy Adult Subjects

Started: 11/12/2018

NCT03450330 Phase 1 COMPLETED

Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer

Started: 4/16/2018

NCT04225208 Phase 1 COMPLETED

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

Started: 1/6/2020

Drug Candidates

GW5282 combined with Golidocitinib Conventional CHOP regimen DZD8586+R-CHOP DZD8586+R-GemOx DZD8586+BR DZD8586 DZD6008 Sunvozertinib sunvozertinib GW5282
Activity Status: Active
Last Trial Started: 4/15/2026
Last Trial Ended: 4/6/2026
Trials (12 months): 8
Completed Trials: 16
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.